US-based firm Proteus Digital Health has developed a pipeline of 31 digital medicines called DigiMeds, in partnership with different organisations, for a variety of health indications.

With Japan-based Otsuka Pharmaceutical, Proteus is developing digital medicines for mental health conditions such as schizophrenia, bipolar and major depressive disorder.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Their ABILIFY MYCITE (aripiprazole tablets with sensor) medicine obtained its first approval in November last year, and the partners are currently working on additional products to tackle mental disorders.

Proteus Digital Health CEO Andrew Thompson said: “Our extensive clinical trial and commercial experience with digital medicines with thousands of patients has been overwhelmingly positive.

“More importantly, we have shown consistently that patients who choose to use DigiMeds take them about 90% of the time, compared to medication possession of 50% with regular drugs.”

“Our extensive clinical trial and commercial experience with digital medicines with thousands of patients has been overwhelmingly positive.”

Proteus formulated 15 DigiMeds for cardiovascular and metabolic conditions. These products can be prepared and delivered through specialist pharmacy services.

For infectious diseases, the firm developed seven digital medicines that are currently undergoing clinical studies involving subjects suffering from tuberculosis (TB), hepatitis C and HIV.

The primary aim of the studies is to validate the use of such medicines in effectively boosting expanded access to curative or life-sustaining drug therapies, while maintaining high adherence.

Furthermore, Proteus is developing a portfolio of products for the treatment of cancer, such as oral agents with a complex dosing schedule and drugs to relieve side effects, including opioid analgesics.

Duke University School of Medicine associate professor Dr Linda Sutton is contributing to the oncology project.

Sutton said: “There is so much uncertainty when prescribing oral oncolytics today. With digital oral chemotherapy drugs, the patient’s oncologist will know with certainty when the patient took his or her chemo.”